about
Home versus hospital intravenous antibiotic therapy for cystic fibrosisPneumococcal vaccines for cystic fibrosisPneumococcal vaccines for cystic fibrosisHome versus hospital intravenous antibiotic therapy for cystic fibrosisInspiratory muscle training for cystic fibrosisDuration of intravenous antibiotic therapy in people with cystic fibrosisDuration of intravenous antibiotic therapy in people with cystic fibrosisPneumococcal vaccines for cystic fibrosisInspiratory muscle training for cystic fibrosisHome intravenous antibiotics for cystic fibrosisEarly anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'Nonparametric estimation of the mean function for recurrent event data with missing event category.Changes in pediatric health-related quality of life in cystic fibrosis after IV antibiotic treatment for pulmonary exacerbations.Respiratory syncytial virus engineered to express the cystic fibrosis transmembrane conductance regulator corrects the bioelectric phenotype of human cystic fibrosis airway epithelium in vitro.Newborn screening for cystic fibrosis: Polish 4 years' experience with CFTR sequencing strategyStudy of the effect of antimicrobial peptide mimic, CSA-13, on an established biofilm formed by Pseudomonas aeruginosa.Relations between depressive and anxious symptoms and quality of life in caregivers of children with cystic fibrosisUnique among ciliopathies: primary ciliary dyskinesia, a motile cilia disorder.A decision-tree approach to cost comparison of newborn screening strategies for cystic fibrosis.Mapping complex disease loci in whole-genome association studies.Electronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftor.Optimal DNA tier for the IRT/DNA algorithm determined by CFTR mutation results over 14 years of newborn screeningPneumococcal vaccines for cystic fibrosis.Duration of intravenous antibiotic therapy in people with cystic fibrosis.Genetic variation of SCNN1A influences lung diffusing capacity in cystic fibrosis.Effects of short indels on protein structure and function in human genomesSerum vascular endothelial growth factor is elevated in cystic fibrosis and decreases with treatment of acute pulmonary exacerbation.
P2860
Q24187116-AC13DEDF-2F1B-473E-85C9-677B8C2BDF79Q24194469-C104A56D-AC00-45D5-8EF8-05F56886A5DDQ24200312-B306BF0C-6097-40E0-A9B8-583413A0D454Q24201353-69354B24-7877-4C1D-8D64-9AF04E1ED81BQ24202380-98145884-EA10-47A2-89D0-B5EA88750992Q24202855-41852CC7-AD1E-4A73-B4C2-35A1706DF500Q24234667-0A18E690-883E-47CB-825A-D7C2BAB1C858Q24236204-3E17DB6F-31AA-4295-8771-BFE81039C96BQ24241004-49A6ADD7-57FD-4843-BDDF-A0A4A7D1E007Q24242785-BA4F1E80-4B77-4AB1-8FB8-C7643D7E4605Q30436229-B92ED218-3FBA-4489-B0FC-80A2B6A8AEEDQ30731623-5C8754A0-CF84-43D2-BD94-E1BAFFA4140FQ33762863-9C94CEC0-1C37-42EC-B5AA-D3F8195E44F3Q33964142-6DC79D6C-3253-48F0-B2F7-137E8D0B3E2CQ34293992-15CC3EDE-B80D-4763-B908-A0DE7DA1C046Q34597849-517BD682-7D08-4E95-90A8-24C0E09012A9Q35008511-54F20D2A-5637-456F-AB65-FA909B803C93Q35210996-DAE563D2-FC46-4451-AAB1-89DF3DE0E65FQ35715179-2883CCAD-BAF8-4928-9558-C6CBAAF0C6EBQ35784516-7E1FD9D4-B984-4497-AAA9-8ED321FA878BQ36054346-690F0DB4-C840-4D79-AFE9-CA5554AD3A69Q36834166-64DC1E4C-ED2D-4B7E-A587-F1CBFC410C50Q38818894-D2B90B25-FF1F-4112-A5A9-76C941EBB434Q38943109-423A7264-0F88-49DA-A720-EB1F8A0678B8Q41510380-FB9A90A9-8FF7-4BDC-8003-9111CF8EEB13Q41516577-4D835880-9F0C-461D-9B52-55B54C3D0478Q45195613-2B610D03-89EE-4017-A698-9FA7CCD9C385
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
The incidence of cystic fibrosis.
@en
The incidence of cystic fibrosis.
@nl
type
label
The incidence of cystic fibrosis.
@en
The incidence of cystic fibrosis.
@nl
prefLabel
The incidence of cystic fibrosis.
@en
The incidence of cystic fibrosis.
@nl
P2093
P1476
The incidence of cystic fibrosis.
@en
P2093
P304
P356
10.1002/(SICI)1097-0258(19960315)15:5<449::AID-SIM173>3.0.CO;2-X
P407
P577
1996-03-01T00:00:00Z